Text Size

A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)

Olander K.W., Sato M.A., Abrams M.A., Jerkins G.W., Lu F., Dinh P., Odani-Kawabata N., Chabi A., Shams N.K.


  • 2021
  • Journal of glaucoma
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    University Eye Specialists, TN, Maryville, United States; East West Eye Institute, Los Angeles, CA; Abrams Eye Center, Cleveland, OH; Advancing Vision Research, TN, Nashville, United States; Santen Inc., Emeryville, CA; Santen Pharmaceutical Co., Ltd.Osaka, Japan

Related Publications

MicroRNA profile of extracellular vesicles released by Müller glial cells

Lamb W D.B.; Eastlake K.; Luis J.; Sharif N.A. ; Khaw P. T.; Limb G. A.


Steroid-Induced Ocular Hypertension in Mice Is Differentially Reduced by Selective EP2, EP3, EP4, and IP Prostanoid Receptor Agonists

Sharif N.A.; Millar J.C.; Zode G.; Ota T.


Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: Two-Year Results from a Randomized, Multicenter Study

Panarelli J.F., Moster M.R., Garcia-Feijoo J., Flowers B.E., Baker N.D., Barnebey H.S., Grover D.S., Khatana A.K., Lee B., Nguyen T., Stiles M.C., Sadruddin O., Khaw P.T., Vold S., McFarland M., Stiles M., Stechschulte A., Strom A., Reynolds A., Noecker R., Thimons J., Khaimi M., Allen E., Sarkisian S., Barnebey H., Golez E., Feldman R., Bell N., Blieden L., Cantor L., WuDunn D., Catoira-Boyle Y., Chen H., Evans J., Martin E., Sozeri Y., Srivastava V., Wise R., Schwartz K., Grover D., Butler M., Emanuel M., Fellman R., Godfrey D., Smith O., Kornmann H., Khatana A., Hagee D., Kuhlman B., Zink J., Moster M., Dale E., Pro M., Baker D., Chambers M., Lehmann D., Caprioli J., Francis B., Giaconi J., Law S., Nouri-Mahdavi K., Coleman A., Flynn W., Rashid E., Reilly C., Rice R., Sidoti P., Panarelli J., Garg R., Tania Tai T.Y., Vinod K., Harizman N., Ritch R., Reiss G., Dewan V., Patel S., Sorenson C., Larsen C., Samuelson T., Hansen M., Barth T., Blakstad A., Buboltz M., Fahmy A., Fahmy M., Montealegre K., Mizener M., Whitted P., Lim M., Brandt J., Baik A., Jiang A., Brown S.V.L., Breunig A.C., Gorla M.S.R., Riss I., Feijoo G., Mendez Hernandez C., Martinez de la Casa J., Dupré Pelaez M., Fernandez Vidal A., García Sáenz S., Morales Fernandez L., Sáenz Francés F., Santos Bueso E., Perucho Gonzalez L., Beckers H.J.M., Kujovic S., Nardi M., Maglionico M.N., Nasini F., Passani A., Strouthidis N., Barton K., Clarke J., Gazzard G., Jayaram H., Khaw P., Papadopoulos M., Puertas R., Toth M., Lunt D., Triolo G., Kam R., Levine J., Flowers B., Nair U., Simmons S., Pokabla M., INN005 Study Group


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022